Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
PRIMARY OBJECTIVES:
I. Evaluate patient perceptions surrounding their quality of life (QOL) prior to pharmacogenomics (PGx) testing and 3 months post PGx testing.
II. Understand the clinical utility/relevancy of PGx testing in cancer patients at Mayo Clinic Arizona from the viewpoint of their providers.
OUTLINE:
Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing.
After completion of study, patients are followed for up to 1 year.
Age
Any age
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patient enrolled to Mayo Clinic IRB: 18-000326
Patients with stage 3 or 4 breast, colorectal, prostate/genitourinary (GU), pancreato-biliary, brain, melanoma, and ovarian cancer
Individuals have agreed to participate and signed the study informed consent form
You may not be if
Patients with cancer types other than the ones mentioned above
Patient with psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
Previous PGx testing with results available within Mayo Clinic electronic medical record (EMR)
